- recruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
United States · Australia · Austria - active not recruitingPHASE3
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to previous platinum-based chemotherapy. It looks at how well adding a drug called relacorilant to nab-paclitaxel works compared to nab-paclitaxel alone.
United States · Argentina · Australia - active not recruitingPHASE3
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
This study looks at a new drug, oregovomab, combined with standard chemotherapy for women with advanced ovarian cancer after surgery. Researchers want to see if this combination works better and is safe compared to chemotherapy alone.
United States · Argentina · Belgium - recruitingNA
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers
This study is building a powerful collection of blood samples, tissue samples, and health information from people with ovarian, fallopian tube, and peritoneal cancers. Its goal is to boost our understanding of these cancers and help scientists develop better ways to diagnose and treat them in the future.
France